Related Experiment Videos
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Irmgard Tegeder1, Gerd Geisslinger
1Pharmazentrum Frankfurt/ZAFES, Institut für Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany. tegeder@em.uni-frankfurt.de
Naunyn-Schmiedeberg'S Archives of Pharmacology
|April 6, 2006
Summary
Cyclooxygenase inhibitors increase cardiovascular risks like heart attack and stroke, particularly with higher doses or longer use. Early identification of at-risk patients using biomarkers may prevent serious adverse events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Cyclooxygenase (COX) inhibitors are widely used for pain and inflammation.
- COX inhibitors are associated with increased risks of myocardial infarction, stroke, hypertension, and heart failure.
Purpose of the Study:
- To review the cardiovascular risks associated with cyclooxygenase inhibitors.
- To explore factors influencing these risks and potential mitigation strategies.
Main Methods:
- Review of randomized clinical trials and observational studies.
- Analysis of mechanisms underlying cardiovascular adverse effects.
- Comparison of selective and unselective COX inhibitors.
Main Results:
- Cardiovascular adverse events are linked to dose and duration of COX inhibitor use.
- Risk is higher in patients with pre-existing cardiovascular risk factors.
- Substance-specific differences exist among COX inhibitors, potentially due to pharmacokinetics or prostaglandin-independent effects.
Conclusions:
- COX inhibitors pose significant cardiovascular risks, influenced by dose, duration, and patient factors.
- Biomarkers like NT-proBNP and hs-CRP may aid in early risk identification.
- Careful patient selection and monitoring are crucial to mitigate cardiovascular toxicity.